INSILICOTRIALS TECHNOLOGIES BV

Their core work

InSilicoTrials Technologies builds computational simulation platforms that allow cardiac devices, drugs, and other medical products to be tested and certified through computer models rather than relying exclusively on physical or animal trials. Their core business is providing validated in-silico trial infrastructure that can be submitted to regulators as evidence for product approval — a practice known as model-based evidence. They also apply AI and data science to clinical decision support for chronic neurological diseases, helping clinicians and patients manage conditions like ALS and multiple sclerosis at home. As a third-party technology provider, they integrate their simulation and AI tools into large research consortia without leading projects themselves.

What they specialise in

How they've shifted over time

Both projects launched simultaneously in 2021, so the keyword split reflects two parallel workstreams rather than a genuine timeline shift. The BRAINTEASER strand — open science, data FAIRness, AI, personalized healthcare, decision support — represents their applied AI capability for patient-facing disease management. The SimCardioTest strand — cardiology, in-silico trials, regulatory approval, medical devices — represents their core commercial product: simulation software positioned directly at the regulatory certification market. The meaningful trend is that the SimCardioTest work is more strategically central: it names the company's own technology in the project title, suggesting in-silico trials for regulatory use is where they invest their deepest IP.

They appear to be sharpening their identity as a regulatory simulation specialist — the SimCardioTest project aligns exactly with their company name and likely their flagship product, suggesting future collaborations will be sought in computational evidence for medical device or drug approval.

How they like to work

InSilicoTrials operates exclusively as a third-party contributor, never coordinating or holding full participant status — a pattern that signals they supply a defined technology or tool to consortia rather than shaping research direction. Despite this limited formal role, their reach across 22 partners in 9 countries is substantial for just two projects, indicating their tools are embedded in large multi-partner consortia. This makes them a plug-in specialist: easy to integrate for their specific simulation or AI capability, but unlikely to anchor or drive a consortium's scientific agenda.

With 22 unique consortium partners across 9 countries from only two projects, their network is dense relative to their project count — both BRAINTEASER and SimCardioTest are large multi-partner RIA consortia. Their European footprint spans multiple health research ecosystems without visible geographic concentration.

What sets them apart

InSilicoTrials is one of the few commercial companies in Europe whose entire product line is built around replacing or supplementing physical clinical trials with validated computer simulations — a niche with growing regulatory acceptance from EMA and FDA under their modeling and simulation frameworks. Unlike academic groups doing computational modeling as a research output, InSilicoTrials produces simulation software as a commercial product designed for regulatory submission, which means a consortium partner gets a tool with certification ambitions, not just a research prototype. For anyone building a consortium around medical device development, drug testing, or digital health regulation, they bring something no university partner typically provides: simulation-as-evidence with a commercial maintenance and compliance track.

Highlights from their portfolio

• SimCardioTest
  Directly mirrors the company's core product — computational simulation for cardiac device and drug certification — making this the clearest evidence of what InSilicoTrials actually sells, and positioning their in-silico trial platform within EU regulatory pathways.
• BRAINTEASER
  Demonstrates their AI capability extends beyond simulation into patient-facing clinical decision support for rare neurological diseases (ALS, MS), broadening their profile beyond cardiology and devices.